Raj Agrawal

Learnings from software and technology

  • Home
  • Technology
  • Software
  • Work
  • Play

Connect

  • GitHub
  • LinkedIn
  • YouTube

Powered by Genesis

You are here: Home / Archives for Raj Agrawal

Augmented Reality Technology Meets A Revolution

November 20, 2012 by Raj Agrawal Leave a Comment

UPCOMING TECHNOLOGY – Remember in the film Minority Report when the operators are fiddling around with their systems in a 3D space? And remember how there were those virtual reality things that put you straight in to an immersive environment? Both of those things are right round the corner – the Leap Motion device, an incredibly precise 3D tracking suite, and the Oculus Rift, a next-generation head-tracking stereoscopic virtual reality headset, are going to completely change the world. Here’s an introduction to both of them, and an explanation of how they will work together to revolutionise computing.

What is Leap Motion?

In the video above, you can notice that Leap Motion is a device not much larger than an iPod. It sits wirelessly on a desk and creates a virtual cubic metre of point tracking space. That means it can detect your hands, your body or any object you suspend in a cubic metre of 3D space before it. It can track well over a million points at once – over a thousand times more accurately than current tracking technology such as the Microsoft Kinect – and can discriminate between a finger, a pencil and palms. It supports whole new ways to interact with your computer, from using chopsticks to pull Google Earth about to using a playground-style pistol-shaped fist to play first-person shooters. Leap Motion – Founded in 2010 as OcuSpec, the startup raised a $1.3M seed financing round in June 2011 with investments from venture capital firms Andreessen Horowitz and Founders Fund as well as several angel investors – An excerpt from Wikipedia.


What is Oculus Rift?

The Oculus Rift is revolutionary too, but in a completely different way. Current virtual reality headsets suffer from two main problems. The first is the speed of head tracking: as the head moves, the view shifts with noticeable latency. The second is the field of view: users of VR headsets currently have about an 40 degree field of vision, well below the 130-degree field of vision (average) of normal sight.

The Rift solves both of those problems. It contains revolutionary head-tracking technology enabling virtually instant view transitioning based on the user’s movements. It also ups the field of vision to 110 degrees – just off that of normal sight. It is, in both senses, totally immersive.

The company announced a Kickstarter campaign on 1 August 2012. Within four hours of the announcement, Oculus secured its objective of $250,000 to further develop the headset. In less than 36 hours, the Kickstarter campaign surpassed $1 million dollars in funding, eventually ending with $2,437,429 in funding – An excerpt from Wikipedia.


So what about the two together?

There’s the most exciting part. Leap claimed that the original idea for the Motion came out of the difficulty of 3D modelling. Something so simple in real life, they believe, should not be so difficult on a computer. And so, the Leap allows you to manipulate virtual clay in to any sort of structure you want – incredibly realistically. Oculus Rift slots straight into this, of course. Manipulating a 3D model on-screen is all very good and well, but real sculptors need to be able to see the shape they create before them.

One of the unexpected benefits of the Motion and the Rift is that the device a program is being run on will become less important. This could see the end of desktop computers altogether – both devices are so portable that fully-immersive computing will be possible using a quality, powerful notebook or laptop. Remove the static media, and you remove the static category – perhaps this will be the catalyst the notebook industry needs to continue its meteoric rise.

The Oculus Rift will be available as Developer Kits from January 2013, with the Leap Motion Dev Kits already shipping. End-user products are available to pre-order from both company websites.

Filed Under: Technology Tagged With: augmented, Oculus Rift

Ubuntu is still half baked. It cannot replace Windows or OS X!

November 10, 2012 by Raj Agrawal 9 Comments

Note – This article was written in the year 2012 and does not reflect the current state of Ubuntu.

RANT – My peers have asserted – ‘I have downloaded my free OS. I am ditching Windows and switching to Ubuntu’. As a technology enthusiast, it’s always a moment of excitement in a open source initiative, particularly when it’s an Operating System. Having said that, Ubuntu left me disappointed.

OS X vs Linux vs Windows

There are plenty of free Linux derivatives around to try. They’re like delicious-and-ready-to-eat-candies lying around the web. I’ve tried a few of them (Sabayon, Open SUSE, Mandriva, Fedora and a few more), and among the list, I particularly liked Damn Small Linux. It’s cute and only 50MB in size. It doesn’t raise many expectations as a user nor does it explicitly claim/ imply to be a desktop replacement.

Apparently, Ubuntu is popularly believed to be a complete desktop replacement. And with so many too-good-to-be-true words and promotions about Ubuntu (back in the days), I thought ‘Ubuntu could be my new permanent OS’. Sadly, that didn’t work out. Even though my computer’s (Macbook Pro 13 Mid-2010) hardware specifications are more than recommended for Ubuntu; it was still very sluggish. The setting panels and apps took their own time to execute. The default pack of applications still include Firefox browser, which is just another layer to discomfort. And it’s not just my computer – it’s a known problem. With such minor usability issues on hand, it’s too soon to claim Ubuntu as a desktop replacement. It isn’t completely reliable yet.

Update – There are mixed experiences regarding the ‘sluggish-ness’ issue. Some users are having no problems, while some are facing severe performance issues even on systems with enough hardware specifications. A google search on this issue will help you undersand more.

Windows and OS X have been under closed development much before Ubuntu was born. Due to Ubuntu’s open source nature, it is maintained by a large developer community from around the world and it still has time grow into a complete and reliable operating system.

Sluggishness and incompatibility does NOT fit in the criteria of a reliable operating system. Ubuntu is NOT YET a suitable Windows/ OS X replacement.

Filed Under: Technology Tagged With: ubuntu, windows

Nanotechnology And Anti-Cancer Therapeutics

November 7, 2012 by Raj Agrawal Leave a Comment

Nanotechnology is a science that has helped mankind seek solutions, which is otherwise impossible on a macro scale. Over the course of time, a myriad of new applications and formulations have been developed to tackle the problems encountered while preparing conventional medical formulations. In this article, i’ll talk about a few devices which have been built using the principles of nanotechnology.[1] Nanotechnology aims at targeting the specific delivery of therapeutic agents (medications), which have been known to reduce the toxicities in other organs. And this has been a major concern in cancer therapy. The therapeutic agents are conventionally directed towards the patient’s cells that have lost apoptotic control and that are growing limitlessly.[2] These medications are directed towards human cancerous cells, it becomes difficult to select the right target, and hence the therapeutic agents end up killing the normal body cells.

A Solution In Research

Nanotechnology directs the therapeutic agents to target a specific organ and also help save other organs from being killed. Many of the recent anti-cancer drugs failed the clinical trials due to safety concerns, but as genuine fix to the concern, they are now being formulated using nanotechnology. Wortmannin, a potent anti-cancer drug that acts as an inhibitor of Phosphoinositol 3-kinase[3] had failed the clinical trials due to problems related to toxicity, solubility and stability. It was later re-formulated as a nanoparticle where the researchers have claimed to solve all the aforementioned problems that earlier caused it’s failure.[4]

Wortmannin bound to target. Image credit: wortmannin.noneto.com
Wortmannin bound to target (Image credit: wortmannin.noneto.com)

Similarly, researchers have successfully experimented to develop nanoparticles which comprise small chains of magnetic particles (Nanochains) and liposomes loaded with doxorubicin. This was tried in rodent models for triple-negative breast cancer.[5] By doing so, researchers reported that the toxicity was reduced remarkably and as the formulation was loaded with liposomes and made target specific the dose also reduced considerably.

Nano-chain targetting
Nano-chain targeting (Image credit: spectroscopynow.com)

The action of this formulation was such that when the liposomes reached the target organ or site of cancerous growth, magnetic nanoparticles were stimulated by electric field which made them vibrate due to which the liposome membrane would disrupt and the drug directly releasing on the cancerous cells. The targeting was based on αvβ3 integrin-targeted nanochain particle composed of four iron oxide nanospheres chemically linked in a linear assembly. The αvβ3 integrin is an adhesion receptor expressed by breast cancer cells and osteoclasts. [6]

References

  1. Martis, E.A., R.R. Badve, and M.D. Degwekar, Nanotechnology based devices and applications in medicine: An overview. Chronicles of Young Scientists. 3(1): p. 68.
  2. Lowe, S.W. and A.W. Lin, Apoptosis in cancer. Carcinogenesis, 2000. 21(3): p. 485-495.
  3. Weng, L.P., J.L. Brown, and C. Eng, PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and‐independent pathways. Human molecular genetics, 2001. 10(3): p. 237-242.
  4. Karve, S., et al., Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proceedings of the National Academy of Sciences. 109(21): p. 8230-8235.
  5. Peiris, P.M., et al., Imaging Metastasis Using an Integrin-Targeting Chain-Shaped Nanoparticle. ACS nano. 6 (10), pp 8783–8795
  6. Zhao, Y., et al., Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer research, 2007. 67(12): p. 5821-5830.

Filed Under: Technology Tagged With: nano

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 79
  • Next Page »